How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not
Open Access
- 17 July 2021
- journal article
- review article
- Published by Elsevier BV in Kidney International
- Vol. 100 (6), 1185-1189
- https://doi.org/10.1016/j.kint.2021.06.036
Abstract
No abstract availableThis publication has 43 references indexed in Scilit:
- Structural basis for the cyclophilin A binding affinity and immunosuppressive potency ofE-ISA247 (voclosporin)Acta crystallographica. Section D, Structural biology, 2011
- Renal Transplant Patients at High Risk of Acute Rejection Benefit From Adequate Exposure to Mycophenolic AcidTransplantation, 2010
- Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant PatientsClinical Journal of the American Society of Nephrology, 2010
- Limited Sampling Models and Bayesian Estimation for Mycophenolic Acid Area under the Curve Prediction in Stable Renal Transplant Patients Co-Medicated with Ciclosporin or SirolimusClinical Pharmacokinetics, 2009
- Population Pharmacokinetics of Mycophenolic AcidClinical Pharmacokinetics, 2008
- Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant RecipientsClinical Pharmacokinetics, 2007
- A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patientsBritish Journal of Clinical Pharmacology, 2006
- Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant RecipientsClinical Pharmacokinetics, 2005
- Review of the immunosuppressant enteric-coated mycophenolate sodiumExpert Opinion on Pharmacotherapy, 2004
- Clinical Pharmacokinetics of Mycophenolate MofetilClinical Pharmacokinetics, 1998